Cargando…
973. Pharmacokinetic/Pharmacodynamic Evaluation and Dose Optimization of Daptomycin in Pediatric Patients with Staphylococcus aureus Bacteremia
BACKGROUND: Optimal dosing of daptomycin (DAP) in pediatric patients has not been elucidated in clinical practice. This study was conducted to examine DAP exposures achieved with package label dosing (PLD) and identify dosing regimens necessary to optimize efficacy and mitigate toxicity in pediatric...
Autores principales: | Olney, Katie B, Howard, Joel I, Burgess, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677369/ http://dx.doi.org/10.1093/ofid/ofad500.028 |
Ejemplares similares
-
2554. What’s Weight Got to Do with It? Prospective Pharmacokinetic/Pharmacodynamic Evaluation of Fixed-Dose Daptomycin
por: Olney, Katie B, et al.
Publicado: (2023) -
117. Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia
por: Cheng, Matthew P, et al.
Publicado: (2020) -
1507. Pharmacodynamic Target Attainment of Daptomycin Against Staphylococcus aureus for Treatment of Pediatric Osteomyelitis
por: Stimes, Grant, et al.
Publicado: (2019) -
Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin
por: Bamberger, David M
Publicado: (2007) -
Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach
por: Garonzik, Samira M., et al.
Publicado: (2016)